Physician profile
Douglas Dewayn Heldreth
NPI 1699766378
$9,804.98
in general payments reported to CMS, 2019-2025
65 companies · $1,119 in 2025
The $1,119 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $941 · 2021: $666 · 2022: $1,640 · 2023: $1,657 · 2024: $2,734 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,429 · Education: $80.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,429.11 |
| Education | $80.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $791.10 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $685.10 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $624.26 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $564.11 | 2022-2025 | Myrisk |
| Novartis Pharmaceuticals Corporation | $478.68 | 2019-2025 | |
| Janssen Biotech, INC. | $434.13 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Celgene Corporation | $429.40 | 2019-2025 | Opdualag, Reblozyl |
| Astellas Pharma US INC | $394.88 | 2019-2025 | Xospata, Xtandi, Padcev |
| Incyte Corporation | $341.46 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Astrazeneca Pharmaceuticals LP | $320.93 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Amgen INC. | $313.27 | 2019-2023 | Kyprolis |
| Seagen INC. | $283.28 | 2020-2023 | Padcev, Tukysa |
| Gilead Sciences, INC. | $280.71 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $251.06 | 2019-2024 | |
| Sobi, INC | $222.04 | 2022-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Heldreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.